Divi's Laboratories Limited — Q1FY27 Earnings Call Summary

DIVISLAB · Q1FY27 · Filed 06 Aug 2026

Key Takeaways

• Ongoing capex projects nearing completion; validation batches progressing
• Gross margin approx. 68% in Q1; full-year margin expected near last year's level
• Q1 FY27 consolidated total income ₹3,144 Cr (+24% y-y); PAT ₹902 Cr (+65% y-y)
• Regulatory approvals key for commercial ramp-up of new projects
• Management targets sustained double-digit revenue growth for FY27
• Peptide capacity expanding with new 3,000-liter SPPS installations
• Custom Synthesis contributed 60% of revenue; Generics 40%
• Supply chain challenges persist; 3-month inventory buffer maintained
• Nutraceutical revenue ₹298 Cr (+19% y-y)
• Unit 3 supports backward integration; overall plant utilization ~85%

📄 Source: View original transcript (PDF)

Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.